FXYD2 and cancer: Upregulation of FXYD2 in cancer cells has been shown to confer dependence on FXYD2 for survival, and the inhibition of Na+/K+-ATPase by cardiac glycosides has a great therapeutic efficacy in OCCC cells expressing high levels of FXYD2 through an autophagic effect.